Pim Kinase Inhibition Disrupts CXCR4 Signalling in Megakaryocytes and Platelets by Reducing Receptor Availability at the Surface
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25147606 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Sophie H Nock und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester M1 5GD, UK. Hauptthemen laut MEDLINE: Receptors, CXCR4, Blood Platelets, Megakaryocytes, Signal Transduction. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, British Heart Foundation Project Grant, British Heart Foundation PhD Studentship.
Abstract (Originalsprache)
A key step in platelet production is the migration of megakaryocytes to the vascular sinusoids within the bone marrow. This homing is mediated by the chemokine CXCL12 and its receptor CXCR4. CXCR4 is also a positive regulator of platelet activation and thrombosis. Pim-1 kinase has been shown to regulate CXCR4 signalling in other cell types, and we have previously described how Pim kinase inhibitors attenuate platelet aggregation to CXCL12. However, the mechanism by which Pim-1 regulates CXCR4 signalling in platelets and megakaryocytes has yet to be elucidated. Using human platelets, murine bone marrow-derived megakaryocytes, and the megakaryocyte cell line MEG-01, we demonstrate that pharmacological Pim kinase inhibition leads to reduced megakaryocyte and platelet function responses to CXCL12, including reduced megakaryocyte migration and platelet granule secretion. Attenuation of CXCL12 signalling was found to be attributed to the reduced surface expression of CXCR4. The decrease in CXCR4 surface levels was found to be mediated by rapid receptor internalisation, in the absence of agonist stimulation. We demonstrate that pharmacological Pim kinase inhibition disrupts megakaryocyte and platelet function by reducing constitutive CXCR4 surface expression, decreasing the number of receptors available for agonist stimulation and signalling. These findings have implications for the development and use of Pim kinase inhibitors for the treatment of conditions associated with elevated circulating levels of CXCL12/SDF1α and increased thrombotic risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Life Sciences, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester M1 5GD, UK.
- Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 3AA, UK.
ORCID-Profile: Maria R Blanco-Lopez, Sarah Jones, Amanda J Unsworth
Förderung
- British Heart Foundation
- British Heart Foundation Project Grant
- British Heart Foundation PhD Studentship
- CSL Behring Professor Heimburger Award 2023
- British Heart Foundation Project
- Professor Heimburger Award from CSL Behring
Zitieren
APA
Nock, S. H., Blanco-Lopez, M. R., Stephenson-Deakin, C., Jones, S., & Unsworth, A. J. (2024). Pim Kinase Inhibition Disrupts CXCR4 Signalling in Megakaryocytes and Platelets by Reducing Receptor Availability at the Surface. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147606
Vancouver
Nock SH, Blanco-Lopez MR, Stephenson-Deakin C, Jones S, Unsworth AJ. Pim Kinase Inhibition Disrupts CXCR4 Signalling in Megakaryocytes and Platelets by Reducing Receptor Availability at the Surface. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147606
BibTeX
@article{Nock2024,
author = {Nock, Sophie H and Blanco-Lopez, Maria R and Stephenson-Deakin, Chloe and Jones, Sarah and Unsworth, Amanda J},
title = {Pim Kinase Inhibition Disrupts CXCR4 Signalling in Megakaryocytes and Platelets by Reducing Receptor Availability at the Surface},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25147606}
}
EUVIMED